NBIX News and Press, Neurocrine Biosciences Inc. From 03/02/21

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) - Negative Outcome on Primary Endpoint Measured by the Change...

Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference PR Newswire SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41 st Annual Health Care Conference at 1:30 p.m. Ea...

Neurocrine had already informed investors about weak fourth quarter Ingrezza sales, but AbbVie sales of Orilissa and Oriahnn were weak again, and Ongentys missed expectations as well. Management is upping its marketing spend, likely focusing on getting docs more comfortable with presc...

Neurocrine Biosciences ([[NBIX]] +1.4%) is trading higher today despite the Q4 2020 revenue miss as announced yesterday.However, keeping the outperform rating, the analysts at Baird expect the sales to rebound in the coming year as COVID-driven headwinds subside. The price target is...

Neurocrine Biosciences ([[NBIX]] +1.6%) reports Q4 total revenue of $247.9M, +1.6% Y/Y, misses consensus by $20M.GAAP R&D $66.7M vs. last year's $55.3M.Non-GAAP R&D of $59.4 vs. last year's $47.9M.At December 31, 2020, the Company had cash, cash equivalents and debt securities av...

Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q4 2020 Earnings Call Feb 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcrip...

Neurocrine Biosciences, Inc. (NBIX) Q4 2020 Earnings Conference Call February 04, 2021 04:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Be...

The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Neurocrine Biosciences, Inc. 2020 Q4 - Results - Earnings Call Presentation

Neurocrine Biosciences (NBIX): Q4 Non-GAAP EPS of $0.91 beats by $0.01; GAAP EPS of $3.58 beats by $2.97.Revenue of $247.9M (+1.6% Y/Y) misses by $12.06M.At December 31, 2020, the Company had cash, cash equivalents and debt securities available-for-sale of $1B.Press Release For further deta...

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Res...